Discover KRAZATI® (adagrasib), an oral treatment for adult patients with previously treated KRAS G12C-positive NSCLC or CRC. Learn about safety, testing, and support options.

Find out how KRAZATI® (adagrasib), an oral, FDA approved treatment, works for adult patients with NSCLC and whose tumor has an abnormal KRAS G12C gene.

KRAZATI is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose

Access support for KRAZATI® (adagrasib) NSCLC patients. Get assistance with coverage and care. Download additional resources, including the Patient Brochure and FAQs.

Learn about taking KRAZATI® (adagrasib) for adult patients with KRAS G12C-positive non-small cell lung cancer (NSCLC). Follow recommended dosages and manage side effects.

Learn about taking KRAZATI® (adagrasib), including dosages, administration, and side effects for adult patients with KRAS G12-positive colorectal cancer (CRC).

iniciar el tratamiento con KRAZATI y el apoyo que puede ayudarle en su trayecto. + Para obtener información y recursos adicionales, visite www.KRAZATI.com. ¿Qué es KRAZATI? KRAZATI …

Q: What is KRAZATI? A: KRAZATI is a prescription medicine used in adults alone to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be …

Learn about the common driver mutation, significance of biomarker testing, and treatment option with KRAZATI® (adagrasib) for KRAS G12C-positive non-small cell lung cancer (NSCLC).

KRAZATI is a prescription medicine used in adults: • in combination with a medicine called cetuximab to treat colon or rectal cancer (CRC) • that has spread to other parts of the body or …